A321550 Stock Overview
TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TiumBio Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,730.00 |
| 52 Week High | ₩11,370.00 |
| 52 Week Low | ₩6,290.00 |
| Beta | 0.74 |
| 1 Month Change | -1.28% |
| 3 Month Change | -2.03% |
| 1 Year Change | -26.03% |
| 3 Year Change | -56.45% |
| 5 Year Change | n/a |
| Change since IPO | -42.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| A321550 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 6.2% | 4.2% | 0.8% |
| 1Y | -26.0% | 7.3% | 6.3% |
Return vs Industry: A321550 underperformed the KR Biotechs industry which returned 7.3% over the past year.
Return vs Market: A321550 underperformed the KR Market which returned 6.3% over the past year.
Price Volatility
| A321550 volatility | |
|---|---|
| A321550 Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A321550 has not had significant price volatility in the past 3 months.
Volatility Over Time: A321550's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 51 | Huntaek Kim | www.tiumbio.com |
TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company’s products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, NCE604, NCE611, and NBP. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates.
TiumBio Co., Ltd. Fundamentals Summary
| A321550 fundamental statistics | |
|---|---|
| Market cap | ₩199.92b |
| Earnings (TTM) | -₩17.91b |
| Revenue (TTM) | ₩4.90b |
40.8x
P/S Ratio-11.2x
P/E RatioIs A321550 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A321550 income statement (TTM) | |
|---|---|
| Revenue | ₩4.90b |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩4.90b |
| Other Expenses | ₩22.81b |
| Earnings | -₩17.91b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -692.54 |
| Gross Margin | 100.00% |
| Net Profit Margin | -365.62% |
| Debt/Equity Ratio | 54.4% |
How did A321550 perform over the long term?
See historical performance and comparison